Compare COGT & ALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | ALK |
|---|---|---|
| Founded | 2014 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.1B |
| IPO Year | 2018 | 2003 |
| Metric | COGT | ALK |
|---|---|---|
| Price | $34.21 | $49.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $36.21 | ★ $62.92 |
| AVG Volume (30 Days) | 2.2M | ★ 3.2M |
| Earning Date | 05-06-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,871,000.00 | ★ $10,426,000,000.00 |
| Revenue This Year | N/A | $11.19 |
| Revenue Next Year | $1,733.58 | $5.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.09 |
| 52 Week Low | $8.80 | $33.03 |
| 52 Week High | $43.73 | $65.35 |
| Indicator | COGT | ALK |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 63.81 |
| Support Level | $33.26 | $46.38 |
| Resistance Level | $37.69 | $53.20 |
| Average True Range (ATR) | 1.43 | 2.18 |
| MACD | 0.29 | 0.52 |
| Stochastic Oscillator | 78.82 | 78.06 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Alaska Air Group Inc operates two airlines, Alaska and Horizon, in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements. The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary, and Mileage Plan passenger revenue.